贝达药业递表港交所 已成功转型为一家“平台型制药企业”

Core Viewpoint - Beida Pharmaceutical has submitted its third listing application to the Hong Kong Stock Exchange, with Morgan Stanley and CITIC Securities as joint sponsors, following two unsuccessful attempts in 2021 [1][4]. Company Overview - Beida Pharmaceutical is a pioneer in China's innovative drug research and development industry, successfully transforming from a biotech company focused on innovative drug discovery to a leading and profitable biopharmaceutical company [4][5]. - The company has established an integrated platform driven by four core pillars: independent research and development, market expansion, strategic cooperation, and ecosystem construction [4]. Product Pipeline - Beida has launched eight commercialized products, including five innovative drugs and one biosimilar, with a comprehensive pipeline covering key lung cancer targets and expanding into other high-potential treatment areas such as breast cancer, kidney cancer, hematology, and ophthalmology [5][4]. Financial Performance - The company reported revenues of approximately RMB 2.377 billion, RMB 2.456 billion, RMB 2.892 billion, and RMB 1.731 billion for the fiscal years 2022, 2023, 2024, and the first half of 2025, respectively [5][7]. - Net profits for the same periods were approximately RMB 125 million, RMB 334 million, RMB 387 million, and RMB 131 million [5][7].